Study of daratumumab with EPOCH for plasmablastic lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have plasmablastic lymphoma confirmed by biopsy/pathology and appropriate lab markers.
- Your lymphoma is stage II–IV, or stage I but with a high LDH level or a bulky tumor.
- You have measurable tumor on scan (at least 1.5 cm) or disease found in bone marrow.
- Your general health is strong enough for chemotherapy (ECOG 0–2) and key blood counts and organ labs are within limits.
- If you have HIV, your CD4 count is at least 100, you can’t have certain serious past infections in the last year, and you must be on HIV treatment (or start it).
- You can’t be pregnant or breastfeeding, and you must use reliable birth control during treatment and for 3 months after daratumumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
This trial tests a new drug called elranatamab in patients with plasmablastic lymphoma (a rare blood cancer) who have already completed their first treatment. The drug may help prevent the cancer from coming back or growing, and the trial includes patients with and without HIV.
This study tests a new drug called glofitamab combined with standard chemotherapy (RCHOP) for people with HIV who have been newly diagnosed with a type of blood cancer called large B-cell lymphoma. The goal is to see if adding glofitamab helps fight the cancer better than chemotherapy alone.
This Phase 2 trial studies daratumumab (an antibody medicine) for adults whose rare lymph node/immune-related cancers have come back or did not respond to treatment. It may help shrink disease and improve symptoms, including for people living with HIV when their virus is well controlled.
This Phase 2 study tests whether adding daratumumab to standard chemotherapy, followed by a stem cell transplant, can improve outcomes in primary plasma cell leukemia. It aims to see how well this treatment works and whether it’s safe for people who are eligible for intensive therapy and transplant.
Hear when a new Plasmablastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.